Frexalimab New Phase 2 Data Showed Reduction of Key Biomarker of Nerve Cell Damage in Relapsing MS
June 29, 2024
June 29, 2024
PARIS, France, June 29 (TNSres) -- Sanofi, a life sciences company, issued the following news release:
* * *
* Frexalimab high-dose arm observed a 41% reduction in plasma neurofilament light chain (NfL) levels, a biomarker of nerve cell damage, after 48 weeks of treatment
* Data support potential as a first-in-class, high-efficacy, and disease-modifying treatment for people with relapsing MS
* Phase 3 studies of frexalimab in relapsing MS and n . . .
* * *
* Frexalimab high-dose arm observed a 41% reduction in plasma neurofilament light chain (NfL) levels, a biomarker of nerve cell damage, after 48 weeks of treatment
* Data support potential as a first-in-class, high-efficacy, and disease-modifying treatment for people with relapsing MS
* Phase 3 studies of frexalimab in relapsing MS and n . . .